Calendario›SNY›AD-impaCT
AD-impaCT
A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries
Ensayo de Sanofi en Dermatitis Atopic (del registro, en inglés).
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 187
- Centros
- 3
- Fin del objetivo primario
- mar 2023
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en ene 2022.
Qué mide
Percentage of patients achieving an Atopic Dermatitis Control Tool (ADCT) score less than 7 (defined as in control according to ADCT) (del registro, en inglés) (en la semana 24)
Cómo lo describe el promotor
En el documentoEn inglés, del registroPrimary objective: To assess the disease control of moderate to severe atopic dermatitis in patients aged 12 years and above treated with dupilumab therapy using Atopic Dermatitis Control Tool (ADCT) after 24 weeks of treatment. Secondary objectives: * To figure the proportion of patients with reduction of ADCT score by 5 points after 4, 12, and 24 weeks of treatment. * To figure the proportion of patients with ADCT score less than 7 at weeks 4, 12, and 24. * Assess the effectiveness of dupilumab in moderate to severe atopic dermatitis (AD) patients, using the severity score as routine practice SCORing Atopic Dermatitis (SCORAD). * To describe comorbidities related to type 2 inflammation. * To characterize the safety profile of dupilumab in the local Gulf population. * To evaluate treatment satisfaction in the local Gulf population.
Más ensayos de SNY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Avalglucosidase alfa · Mini-COMET | Fase 2 | En marcha, sin reclutar | sep 2019 (real) |
| Yellow fever vaccine | Fase 2 | En marcha, sin reclutar | may 2022 (real) |
| Yellow fever vaccine · VYF02 | Fase 2 | En marcha, sin reclutar | jun 2022 (real) |
| SAR441344 IV | Fase 2 | En marcha, sin reclutar | sep 2022 (real) |
| Meningococcal Polysaccharide | Fase 3 | En marcha, sin reclutar | mar 2023 (real) |
| Isatuximab IV · IRAKLIA | Fase 3 | En marcha, sin reclutar | nov 2024 (real) |
Todos los de SNY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05214326), actualizada en nov 2023.